Pfizer Oncology is at the forefront of a new era in cancer care. Our industry-leading portfolio and pipeline includes game-changing mechanisms of action to attack cancer from multiple angles, including antibody-drug conjugates (ADCs), small molecules, bispecifics and other immunotherapies. Driven by science, we are committed to accelerating breakthroughs to extend and improve the lives of people living with some of the world’s most common cancers.